Literature DB >> 6744049

Bombesin-induced locomotor hyperactivity: evaluation of the involvement of the mesolimbic dopamine system.

D W Schulz, P W Kalivas, C B Nemeroff, A J Prange.   

Abstract

The neuropeptide bombesin was administered centrally to conscious, unrestrained rats. Bombesin caused a dose-dependent increase in locomotor behavior, as well as licking and grooming. The effect on locomotion was most readily elicited when bombesin was infused into the nucleus accumbens, and was attenuated by pretreatment with haloperidol but not atropine or diphenhydramine. Centrally administered bombesin did not change regional levels of dopamine or its principal metabolites.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6744049     DOI: 10.1016/0006-8993(84)90343-3

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  5 in total

Review 1.  A controlled study of Tourette syndrome. VII. Summary: a common genetic disorder causing disinhibition of the limbic system.

Authors:  D E Comings
Journal:  Am J Hum Genet       Date:  1987-11       Impact factor: 11.025

2.  Bombesin receptors as a novel anti-anxiety therapeutic target: BB1 receptor actions on anxiety through alterations of serotonin activity.

Authors:  Zul Merali; Tania Bédard; Nick Andrews; Ben Davis; Alexander T McKnight; M Isabel Gonzalez; Martyn Pritchard; Pam Kent; Hymie Anisman
Journal:  J Neurosci       Date:  2006-10-11       Impact factor: 6.167

3.  Effect of bombesin on thermoregulation of the rabbit.

Authors:  L Janský; W Riedel; E Simon; C Simon-Oppermann; S Vybíral
Journal:  Pflugers Arch       Date:  1987-07       Impact factor: 3.657

4.  A controlled study of Tourette syndrome. I. Attention-deficit disorder, learning disorders, and school problems.

Authors:  D E Comings; B G Comings
Journal:  Am J Hum Genet       Date:  1987-11       Impact factor: 11.025

5.  Stress and eating: a dual role for bombesin-like peptides.

Authors:  Z Merali; S Graitson; J C Mackay; P Kent
Journal:  Front Neurosci       Date:  2013-10-25       Impact factor: 4.677

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.